Pathophysiology and treatment of the dyslipidemia of insulin resistance

Current Cardiology Reports

Volumn 3, Issue 5, 2001, Pages 416-423

  Cohn, Gregory ^a   Valdes, Gerardo ^b   Capuzzi, David M ^b  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; METFORMIN; NICOTINIC ACID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFESTYLE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LACTONES; LIFE STYLE; LIPASE; METFORMIN; NIACIN; RISK FACTORS;

EID: 0035463814     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0059-0     Document Type: Article

References (43)

1. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998, 339:229-234.
2. Dagogo-Jack S, Santiago JV: Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Int Med 1997, 103:1802-1817.
3. Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris prospective study, ten years later. Horm Metab Res 1985, 15(suppl): 41-46.
4. Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. New Engl J Med 1996, 334:952-957.
5. Haffner SM, Miettinen H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997, 103:152-162.
6. Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991, 121:1283-1288.
7. Rett K: The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999, 1(suppl 1):8-6.
8. Festa A, D'Agostino, Jr. R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42-47.
9. Mokdad AH, Serdula Mk, Dietz WH, et al.: The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999, 282:1519-1522.
10. Must A, Spradano J, Coakley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
11. Kwiterovich, Jr. PO: The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000, 86(12 Suppl 1):5-10.
12. Goldberg RB, Capuzzi D: Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001, 21:147-171.
13. Superko HR: Small, dense low-density lipoprotein subclass pattern B: issues for the clinician. Curr Atheroscler Rep 1999, 1:50-57.
14. O'Keefe, Jr. JH, Miles JM, Harris WH, et al.: Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999, 74:171-180.
15. Knopp RH: Current concepts in dietary therapy for dyslipidemia. In Mediguide to Heart Diseases. Edited by AM Gotto, Jr. New York: Lawrence DellaCorte; 2000, 3:1-8.
16. O'Keefe, Jr. JH, Harris WS: From inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000, 75:607-614.
17. Shikany JM, White Jr. GL: Dietary guidelines for chronic disease prevention. South Med J 2000, 93:1138-1151.
18. Lynch J, Helmrich SP, Lakka TA, et al.: Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin- dependent diabetes mellitus in middle-aged men. Arch Int Med 1996, 156:1307-1314.
19. Henry RR: Glucose control and insulin resistance in non-insulin- dependent diabetes mellitus. Ann Int Med 1996, 124(suppl 1):97-103.
20. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Arch Int Med 1998, 158:1855-1867.
21. Davidson MH, Hauptman J, DiGirolamo M, et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235-242.
22. Heymsfield SB, Segal KR, Hauptman J, et al.: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med 2000, 160:1321-1326.
23. Lindgarde F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Int Med 2000, 248:245-254.
24. Grosskopf I, Ringel Y, Charach G, et al.: Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 1997, 20:1598-1602.
25. Charles MA, Morange P, Eschwege E, et al.: Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO 1 Study. Diabetes Care 1998, 21:1967-1972.
26. Mather KJ, Verma S, Anderson TJ: Improved endothelial function with metformin in type 2 diabetes mellitus. Circulation 2001, 37:1344-1350.
27. Defronzo RA: Treatment of type 2 diabetes mellitus: a sound approach based upon its pathophysiology. Lawrenceville: Academy of Medicine of New Jersey; 2001:21-23.
28. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al.: Nonhypoglycemic effects of thiazolidinedones. Ann Int Med 2001, 134:61-71.
29. Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
30. Hansson L, Lindholm LH, Niskanenn L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) Randomized Trial. Lancet 1999, 353:611-616.
31. Baron AD: Vascular reactivity. Amer J Cardiol 1999, 84:25J-27J.
32. Petrie JR, Ueda S, Webb DJ, et al.: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996, 93:1331-1333.
33. Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
34. Haffner SM, Alexander CM, Cook TJ, et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Int Med 1999, 159:2661-2667.
35. Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
36. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
37. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45.
38. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
39. Effect of Fenofibrate on Progression of Coronary Artery Disease in Type 2 Diabetes: The Diabetes Atherosclerosis Intervention Study. Lancet 2001, 357:905-910.
40. Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM: Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000, 2:64-71.
41. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986, 8:1245-1255.
42. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
43. Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA 2000, 284:1263-1270.